Systemic Therapy Education Bulletin

BC Cancer news and updates from across the province for Systemic Therapy teams

Provincial Systemic Therapy Drug Programs Under Consideration

The goal of the Education Bulletin is to support health care staff as they prepare for new treatments and to ensure safe patient care during the administration, distribution and management of new and complex treatments. These new drug treatments may also be delivered to patients prior to formal listing through manufacturer patient support programs or clinical trials. Full details around the funded indications and eligibility criteria will be available in the Protocol Summaries and summarized in the Systemic Therapy Update newsletter once funding decisions have been finalized. More details about the drugs, approved indications, and side effects can be found in the BC Cancer drug monographs, accessible from the Cancer Drug Manual Drug Index.

HNAVCAP

Treatment Programs	Indication: Under Review (Refer to protocol for more details)	Associated Adverse Events
Capecitabine	Treatment of **Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck**	Possible adverse events (**of any grade**): • Anemia • Lymphopenia • Neutropenia • Thrombocytopenia • Fatigue • Hand-foot skin reaction • Rash • Anorexia • Diarrhea • Nausea and vomiting • Stomatitis • Elevated liver function tests

Dosing and Administration Information

Pre-medications:

- **Antiemetic:** not usually required; low to moderate emetogenicity (see SCNAUSEA)

Dosing and Schedule:

- **Oral capecitabine** 1250 mg/m^2 OR 1000 mg/m^2 twice daily with food on days 1 to 14
  - Repeat every 21 days for 6 to 8 cycles

UGUNMPENZ

Treatment Programs	Indication (Refer to protocol for more details)	Associated Adverse Events
Enzalutamide	Treatment of **Non-Metastatic Castration Resistant Prostate Cancer**	Possible adverse events: • Fatigue • Diarrhea • Hot flashes (approximately 20%) • Headache • Muscle/joint pain • Peripheral edema • QT prolongation • Hypertension • Seizure • Potential drug interactions: • Gemfibrozil, warfarin, omeprazole

Dosing and Administration Information

Pre-medications:

- Not needed

Dosing and Schedule:

- **Oral enzalutamide** 160 mg once daily until disease progression or unacceptable toxicity

Additional Protocol Information:

- Enzalutamide is associated with increased blood pressure in approximately 7% of patients. Hypertension rarely leads to discontinuation or dose modification, but may require antihypertensive treatment. Blood pressure will need to be monitored once every 2 weeks for the first three months of enzalutamide therapy. Temporary suspension of enzalutamide is recommended for patients with severe hypertension (greater than 200 mmHg systolic or greater than 110 mmHg diastolic).
- Dose modification options:
  - **Oral enzalutamide** 120 mg once daily
  - **Oral enzalutamide** 80 mg once daily
- Androgen ablative therapy (e.g., LHRH agonist, LHRH antagonist) should be maintained.

Website Resources and Contact Information

CONTACT INFORMATION	EMAIL
To subscribe or update contact information, please contact:	
Provincial Systemic Therapy Program	ProvincialSystemicOffice@bccancer.bc.ca
Systemic Therapy Education Bulletin: http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/education-bulletin	